Clinical pharmacology and metabolic drug delivery systems marked significant progress toward improving patient compliance.
On November 13, 2026, clinical-stage biopharmaceutical company Vivani Medical announced positive top-line clinical findings from its first-in-human Phase 1 SLIM-1 trial evaluating NPM-139. The miniaturized, ultra long-acting subdermal implant demonstrated sustained zero-order systemic release of semaglutide over multiple months. Pharmacokinetic data confirmed NPM-139, utilizing Vivani's proprietary nano-porous osmotic implant architecture, maintained consistent therapeutic plasma concentrations of semaglutide without peak-and-trough variations. Following a single outpatient subdermal insertion, drug elution remained steady across the trial monitoring timeframe.
Compared against existing commercial subcutaneous formulations administered weekly, NPM-139's continuous delivery eliminated rapid serum concentration spikes that trigger gastrointestinal distress. Clinical trial investigators reported negligible incidence rates of nausea and vomiting among enrolled study participants; patient tolerance profiles remained notably favorable and dosing adherence reached exceptional levels. Vivani Medical's clinical development leadership stated that the Phase 1 SLIM-1 findings showed NPM-139 delivered steady therapeutic semaglutide levels over extended durations and offered a promising alternative to weekly self-injections for chronic obesity management.
Novo Nordisk previously executed a feasibility agreement with Vivani to evaluate NPM-139 for long-term weight management. Epidemiological surveys show millions of chronic obesity and type 2 diabetes patients discontinue weekly injectable GLP-1 therapies within twelve months of treatment initiation; frequent discontinuation stems from recurring gastrointestinal side effects and regular injection fatigue, and discontinuation frequently induces rapid rebound weight gain.
Following successful human safety validation, Vivani finalized preparations to initiate a randomized, multi-dose Phase 2 clinical study in patients with obesity. The company completed preliminary consultations with the United States Food and Drug Administration to harmonize primary clinical endpoints.
